TRP通道和乳腺癌:TRP在病理生理发展中的作用
Yu Zhang1, Yanfeng Yi2, Yinghao Shu1
1Key Laboratory of Vector Biology and Pathogen Control of Zhejiang Province, School of Medicine, Huzhou University, Huzhou, China.
暂时受体潜力 (TRP) 道与乳腺癌的进展有关. 准这些道为乳腺癌治疗提供了一个有前途的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 身体生理学 身体生理学
背景情况:
- 暂时受体潜能 (TRP) 通道是生理和病理过程的关键调节者.
- 对TRP通道的失调在癌症发展中越来越被认可.
- 几个TRP通道参与调解瘤进展.
研究的目的:
- 审查TRP通道在乳腺癌发展中的作用.
- 总结TRP通道调节对乳腺癌特征的影响.
- 探索TRP通道作为潜在的治疗点和乳腺癌的预后生物标志物.
主要方法:
- 对调查乳腺癌中TRP通道的研究进行文献综述.
- 对TRP通道参与增殖,亡,自,转移和血管生成的研究进行分析.
- 关于抑制或激活乳腺癌细胞中TRP通道的实验数据的摘要.
主要成果:
- TRP通道与乳腺癌发生有关.
- 调节TRP通道影响乳腺癌的关键过程,如增殖和亡.
- 在乳腺癌模型中,TRP通道活性会影响转移和血管生成.
结论:
- 在乳腺癌的进展中,TRP通道起着重要的作用.
- 准TRP道代表了乳腺癌治疗的潜在可开发策略.
- 进一步研究TRP通道作为预后生物标志物和治疗点是有必要的.
更多相关视频
07:13Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer
Published on: March 26, 2014
09:44Generation of Organ-conditioned Media and Applications for Studying Organ-specific Influences on Breast Cancer Metastatic Behavior
Published on: June 13, 2016
相关概念视频
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Mitogens and the Cell Cycle
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
PI3K/mTOR/AKT Signaling Pathway
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
